Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-07-22
2008-07-22
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252130, C514S326000, C546S208000, C544S111000, C544S359000
Reexamination Certificate
active
07402581
ABSTRACT:
The present invention relates to a compound of the general formula (I) wherein Het is an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring having at least one nitrogen atom; R1 is hydrogen, hydroxy, C1-C4alkyl, C3-C4cycloalkyl, C2-C4alkenyl or C2-C4alkynyl; R2 and R3 is each and independently selected from hydrogen, C1-C4alkyl, C3-C4cycloalkyl, C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, halogen and cyano, provided that R2 and R3 may not both be hydrogen; R4 is C1-C4alkyl, C3-C4cycloalkyl, C2-C4alkenyl or C2-C4alkynyl; Ar is an optionally substituted aromatic ring system selected from pyridinyl; 1-naphthyl; 5,6,7,8-tetrahydro-1-naphthyl; quinolinyl; 2,3-dihydro-1,4-benzodioxinyl; 1,3-benzodioxolyl; 5,6,7,8-tetrahydroquinolinyl; 5,6,7,8-tetrahydroisoquinolinyl; 5,6,7,8-tetrahydroquinazolin-4-yl; 1-benzo[b]thiophen-7-yl; 1-benzo[b]thiophen-4-yl; 1-benzo[b]thiophen-3-yl; isoquinolinyl; quinazolinyl; and indan-4-yl; or Ar is substituted phenyl; or an enantiomer thereof or any salt thereof; to a pharmaceutical composition containing said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of compounds of formula I and to new intermediates used in the preparation thereof.
REFERENCES:
patent: 6013652 (2000-01-01), Maccoss et al.
patent: 625509 (1994-11-01), None
patent: 625509 (1994-11-01), None
patent: 630887 (1994-12-01), None
patent: 790-248 (1997-08-01), None
patent: 791592 (1997-08-01), None
patent: 962457 (1999-12-01), None
patent: WO-95/05377 (1995-02-01), None
patent: WO-95/12577 (1995-05-01), None
patent: WO-95/15691 (1995-06-01), None
patent: WO-96/05193 (1996-02-01), None
patent: WO-96/10568 (1996-04-01), None
patent: WO-96/24582 (1996-08-01), None
patent: WO-97/25322 (1997-07-01), None
patent: WO-97/27185 (1997-07-01), None
patent: WO-99/01451 (1999-01-01), None
patent: WO-00/02859 (2000-01-01), None
patent: WO-00/20003 (2000-04-01), None
patent: WO-00/20389 (2000-04-01), None
patent: WO-00/25766 (2000-05-01), None
patent: WO-00/34243 (2000-06-01), None
patent: WO-02/051807 (2002-07-01), None
patent: WO-03/037889 (2003-05-01), None
“4-Amino-2-(aryl)-butylbenzamines and their Conformationally Constrained Analogues. Potent Antagonists of the Human Neurokinin-2 (NK2) Receptor”, Mackenzie et al., Bioorg. Med. Chem. Lett., vol. 13, No. 13, Jul. 7, 2003, pp. 2211-2215(5); available online May 15, 2003.
Johansson Anders
Persson Joachim
Albireo AB
Habte Kahsay T
White & Case LLP
LandOfFree
Azetidine compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azetidine compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azetidine compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2808155